Literature DB >> 12783368

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Martin Sattler1, James D Griffin.   

Abstract

The BCR-ABL oncogene is generated by the Philadelphia chromosome (Ph) translocation, fusing the BCR gene to the ABL gene. The BCR-ABL fusion protein has elevated ABL tyrosine kinase activity that is critical for transformation of hematopoietic cells. Chronic myelogenous leukemia (CML) cells transformed by BCR-ABL show reduced growth factor requirements and apoptosis, as well as enhanced viability and altered adhesion. The elevated ABL kinase activity leads to chronic activation of signaling pathways that are required for all aspects of transformation. Progression of the disease from chronic phase to blast crisis correlates with additional cytogenetic alterations that are likely to contribute to the failure of traditional therapy. This review describes molecular mechanisms that are thought to be important for transformation by the BCR-ABL oncoprotein and points at pathways for targeted drug development in the treatment of CML. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783368     DOI: 10.1053/shem.2003.50034

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  52 in total

1.  Anti-inflammatory activity of SMP30 modulates NF-κB through protein tyrosine kinase/phosphatase balance.

Authors:  Kyung Jin Jung; Eun Kyeong Lee; Su Jin Kim; Chang Woo Song; Naoki Maruyama; Akihito Ishigami; Nam Deuk Kim; Dong-Soon Im; Byung Pal Yu; Hae Young Chung
Journal:  J Mol Med (Berl)       Date:  2014-11-15       Impact factor: 4.599

2.  Charting the molecular network of the drug target Bcr-Abl.

Authors:  Marc Brehme; Oliver Hantschel; Jacques Colinge; Ines Kaupe; Melanie Planyavsky; Thomas Köcher; Karl Mechtler; Keiryn L Bennett; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

3.  Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

Authors:  Rathi N Pillai; Lisa S Chen; Mary L Ayres; Billie J Nowak; Michael W Thomas; Elizabeth J Shpall; Michael J Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2012-04-23

Review 4.  The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Authors:  Rajesh R Nair; Joel Tolentino; Lori A Hazlehurst
Journal:  Biochem Pharmacol       Date:  2010-04-09       Impact factor: 5.858

5.  Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.

Authors:  Shu-Yue Ren; Elisabeth Bolton; M Golam Mohi; Andrea Morrione; Benjamin G Neel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.

Authors:  Andrew S Dixon; Geoffrey D Miller; Benjamin J Bruno; Jonathan E Constance; David W Woessner; Trevor P Fidler; James C Robertson; Thomas E Cheatham; Carol S Lim
Journal:  Mol Pharm       Date:  2011-12-12       Impact factor: 4.939

7.  Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Onco Targets Ther       Date:  2008-10-01       Impact factor: 4.147

8.  Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.

Authors:  Mariana Serpa; Sabri S Sanabani; Pedro Enrique Dorliac-Llacer; Monika Conchon; Thales Dalessandro Meneguin Pereira; Luciana Nardinelli; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Patricia de Barros Ferreira; Israel Bendit
Journal:  BMC Blood Disord       Date:  2010-11-18

9.  Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling.

Authors:  San-Yuan Chen; Chun-Hsiang Lin; Jiun-Tsai Lin; Yi-Fang Cheng; Han-Min Chen; Shao-Hsuan Kao
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

10.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.